These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34244316)

  • 1. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial.
    Sekine L; Arns B; Fabro BR; Cipolatt MM; Machado RRG; Durigon EL; Parolo E; Pellegrini JAS; Viana MV; Schwarz P; Lisboa TC; Dora JMS; Portich JP; Paz AA; Silla L; Balsan AM; Schirmer FD; Franz JPM; da-Silveira LM; Breunig RC; Petersen V; Sosnoski M; Mesquita NF; Volpato FCZ; Sganzerla D; Falavigna M; Rosa RG; Zavascki AP;
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34244316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
    Devos T; Van Thillo Q; Compernolle V; Najdovski T; Romano M; Dauby N; Jadot L; Leys M; Maillart E; Loof S; Seyler L; Moonen M; Moutschen M; Van Regenmortel N; Ariën KK; Barbezange C; Betrains A; Garigliany M; Engelen MM; Gyselinck I; Maes P; Schauwvlieghe A; Liesenborghs L; Belmans A; Verhamme P; Meyfroidt G;
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34446469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.
    Kirenga B; Byakika-Kibwika P; Muttamba W; Kayongo A; Loryndah NO; Mugenyi L; Kiwanuka N; Lusiba J; Atukunda A; Mugume R; Ssali F; Ddungu H; Katagira W; Sekibira R; Kityo C; Kyeyune D; Acana S; Aanyu-Tukamuhebwa H; Kabweru W; Nakwagala F; Bagaya BS; Kimuli I; Nantanda R; Buregyeya E; Byarugaba B; Olaro C; Mwebesa H; Joloba ML; Siddharthan T; Bazeyo W
    BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34376401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
    ; Estcourt LJ; Turgeon AF; McQuilten ZK; McVerry BJ; Al-Beidh F; Annane D; Arabi YM; Arnold DM; Beane A; Bégin P; van Bentum-Puijk W; Berry LR; Bhimani Z; Birchall JE; Bonten MJM; Bradbury CA; Brunkhorst FM; Buxton M; Callum JL; Chassé M; Cheng AC; Cove ME; Daly J; Derde L; Detry MA; De Jong M; Evans A; Fergusson DA; Fish M; Fitzgerald M; Foley C; Goossens H; Gordon AC; Gosbell IB; Green C; Haniffa R; Harvala H; Higgins AM; Hills TE; Hoad VC; Horvat C; Huang DT; Hudson CL; Ichihara N; Laing E; Lamikanra AA; Lamontagne F; Lawler PR; Linstrum K; Litton E; Lorenzi E; MacLennan S; Marshall J; McAuley DF; McDyer JF; McGlothlin A; McGuinness S; Miflin G; Montgomery S; Mouncey PR; Murthy S; Nichol A; Parke R; Parker JC; Priddee N; Purcell DFJ; Reyes LF; Richardson P; Robitaille N; Rowan KM; Rynne J; Saito H; Santos M; Saunders CT; Serpa Neto A; Seymour CW; Silversides JA; Tinmouth AA; Triulzi DJ; Turner AM; van de Veerdonk F; Walsh TS; Wood EM; Berry S; Lewis RJ; Menon DK; McArthur C; Zarychanski R; Angus DC; Webb SA; Roberts DJ; Shankar-Hari M
    JAMA; 2021 Nov; 326(17):1690-1702. PubMed ID: 34606578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).
    Bajpai M; Maheshwari A; Dogra V; Kumar S; Gupta E; Kale P; Saluja V; Thomas SS; Trehanpati N; Bihari C; Agarwal R; Bharti P; Shankar P; Hussain J; Chhabra K; Gupta A; Narayanan A; Agarwal S; Jain S; Bhardwaj A; Kumar G; Yadav BK; Sarin SK
    BMJ Open; 2022 Apr; 12(4):e055189. PubMed ID: 35387813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.
    Avendaño-Solá C; Ramos-Martínez A; Muñez-Rubio E; Ruiz-Antorán B; Malo de Molina R; Torres F; Fernández-Cruz A; Calderón-Parra J; Payares-Herrera C; Díaz de Santiago A; Romera-Martínez I; Pintos I; Lora-Tamayo J; Mancheño-Losa M; Paciello ML; Martínez-González AL; Vidán-Estévez J; Nuñez-Orantos MJ; Saez-Serrano MI; Porras-Leal ML; Jarilla-Fernández MC; Villares P; de Oteyza JP; Ramos-Garrido A; Blanco L; Madrigal-Sánchez ME; Rubio-Batllés M; Velasco-Iglesias A; Paño-Pardo JR; Moreno-Chulilla JA; Muñiz-Díaz E; Casas-Flecha I; Pérez-Olmeda M; García-Pérez J; Alcamí J; Bueno JL; Duarte RF;
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34473652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan.
    Khan TNS; Mukry SN; Masood S; Meraj L; Devrajani BR; Akram J; Fatima N; Maqsood S; Mahesar A; Siddiqui R; Ishaque S; Afzal MB; Mukhtar S; Ahmed S; Naz A; Shamsi TS
    BMC Infect Dis; 2021 Sep; 21(1):1014. PubMed ID: 34579646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
    Li L; Zhang W; Hu Y; Tong X; Zheng S; Yang J; Kong Y; Ren L; Wei Q; Mei H; Hu C; Tao C; Yang R; Wang J; Yu Y; Guo Y; Wu X; Xu Z; Zeng L; Xiong N; Chen L; Wang J; Man N; Liu Y; Xu H; Deng E; Zhang X; Li C; Wang C; Su S; Zhang L; Wang J; Wu Y; Liu Z
    JAMA; 2020 Aug; 324(5):460-470. PubMed ID: 32492084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
    Alemany A; Millat-Martinez P; Corbacho-Monné M; Malchair P; Ouchi D; Ruiz-Comellas A; Ramírez-Morros A; Rodríguez Codina J; Amado Simon R; Videla S; Costes G; Capdevila-Jáuregui M; Torrano-Soler P; San José A; Bonet Papell G; Puig J; Otero A; Ruibal Suarez JC; Zarauza Pellejero A; Llopis Roca F; Rodriguez Cortez O; Garcia Garcia V; Vidal-Alaball J; Millan A; Contreras E; Grifols JR; Ancochea À; Galvan-Femenia I; Piccolo Ferreira F; Bonet M; Cantoni J; Prat N; Ara J; Forcada Arcarons A; Farré M; Pradenas E; Blanco J; Àngel Rodriguez-Arias M; Fernández Rivas G; Marks M; Bassat Q; Blanco I; Baro B; Clotet B; Mitjà O;
    Lancet Respir Med; 2022 Mar; 10(3):278-288. PubMed ID: 35150610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Menichetti F; Popoli P; Puopolo M; Spila Alegiani S; Tiseo G; Bartoloni A; De Socio GV; Luchi S; Blanc P; Puoti M; Toschi E; Massari M; Palmisano L; Marano G; Chiamenti M; Martinelli L; Franchi S; Pallotto C; Suardi LR; Luciani Pasqua B; Merli M; Fabiani P; Bertolucci L; Borchi B; Modica S; Moneta S; Marchetti G; d'Arminio Monforte A; Stoppini L; Ferracchiato N; Piconi S; Fabbri C; Beccastrini E; Saccardi R; Giacometti A; Esperti S; Pierotti P; Bernini L; Bianco C; Benedetti S; Lanzi A; Bonfanti P; Massari M; Sani S; Saracino A; Castagna A; Trabace L; Lanza M; Focosi D; Mazzoni A; Pistello M; Falcone M;
    JAMA Netw Open; 2021 Nov; 4(11):e2136246. PubMed ID: 34842924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.
    Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC;
    Trials; 2020 Jul; 21(1):646. PubMed ID: 32665040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
    Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S
    Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.